Yuhan's Gaucher Disease Drug Candidate Receives Orphan Drug Designation from US FDA
Yuhan Corporation announced on April 13 that its new drug candidate ‘YH35995,’ currently under development as a treatment for Gaucher disease, has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA).
The exterior of the headquarters of Yuhan Corporation in Daebang-dong, Dongjak-gu, Seoul. Yuhan Corporation
View original imageThe FDA’s orphan drug designation is a system aimed at promoting the development of treatments for rare diseases that affect a small number of patients and have limited therapeutic options. Designated drugs are eligible for development incentives such as tax credits for clinical trials, exemption from FDA application fees, and up to seven years of market exclusivity upon approval.
Gaucher disease is a lysosomal storage disorder (LSD) caused by a deficiency of a specific enzyme, which leads to metabolic abnormalities in the body. It is a hereditary rare disease that causes a range of systemic symptoms, including enlargement of the liver and spleen, anemia, thrombocytopenia, and skeletal symptoms. In particular, type 3 Gaucher disease is characterized by accompanying neurological symptoms. There are currently no approved treatments for these neurological manifestations, resulting in a high unmet medical need in this area.
YH35995 is an inhibitor of glucosylceramide synthase (GCS) that reduces the production of glucosylceramide (GL1), and is an oral small molecule compound developed as a substrate reduction therapy (SRT). According to the company, preclinical studies demonstrated that, based on its blood-brain barrier (BBB) permeability, YH35995 showed a strong and sustained reduction of GL1 in the brain. Based on these findings, Yuhan Corporation expects the drug to provide clinical benefits to patients with type 3 Gaucher disease, for whom treatment options for neurological symptoms are limited.
With the orphan drug designation for YH35995, Yuhan Corporation plans to focus on further development aimed at increasing patient access by systematizing its global clinical development and regulatory strategy. The company previously received clinical phase 1 investigational new drug (IND) approval for YH35995 from the Ministry of Food and Drug Safety and is currently conducting first-in-human (FIH) studies to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug in healthy volunteers.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Yeol Hong Kim, Chief R&D Officer at Yuhan Corporation, stated, “The FDA’s orphan drug designation is recognition of both the need to develop new treatment options for patients with type 3 Gaucher disease and the potential of YH35995. Based on collaboration with global regulatory authorities, we will accelerate clinical development to provide practical treatment alternatives for patients with rare diseases.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.